[go: up one dir, main page]

WO2004067774A2 - Polymorphismes de nucleotide simple utilises en tant que diagnostics predictifs d'effet indesirable (adr) et d'efficacite d'un medicament - Google Patents

Polymorphismes de nucleotide simple utilises en tant que diagnostics predictifs d'effet indesirable (adr) et d'efficacite d'un medicament Download PDF

Info

Publication number
WO2004067774A2
WO2004067774A2 PCT/EP2004/000539 EP2004000539W WO2004067774A2 WO 2004067774 A2 WO2004067774 A2 WO 2004067774A2 EP 2004000539 W EP2004000539 W EP 2004000539W WO 2004067774 A2 WO2004067774 A2 WO 2004067774A2
Authority
WO
WIPO (PCT)
Prior art keywords
gene
polypeptide
polymoφhic
drug
genes
Prior art date
Application number
PCT/EP2004/000539
Other languages
English (en)
Other versions
WO2004067774A3 (fr
Inventor
Udo Stropp
Stephan Schwers
Harald Kallabis
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Priority to EP04704556A priority Critical patent/EP1592808A2/fr
Publication of WO2004067774A2 publication Critical patent/WO2004067774A2/fr
Publication of WO2004067774A3 publication Critical patent/WO2004067774A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Definitions

  • Heart failure is defined as a pathophysiologic state in which an abnormality of cardiac function is responsible for the failure of the heart to pump blood at a rate commensurate with the requirement of the metabolizing tissue. It includes all forms of pumping failure such as high-output and low-output, acute and chronic, right- sided or left-sided, systolic or diastolic, independent of the underlying cause.
  • MI Myocardial infarction
  • the first observable event in the formation of an atherosclerotic plaque occurs when blood-borne monocytes adhere to the vascular endothelial layer and transmigrate through to the sub-endothelial space. Adjacent endothelial cells at the same time produce oxidized low density lipoprotein (LDL). These oxidized LDLs are then taken up in large amounts by the monocytes through scavenger receptors expressed on their surfaces. In contrast to the regulated pathway by which native LDL (nLDL) is taken up by nLDL specific receptors, the scavenger pathway of uptake is not regulated by the monocytes.
  • LDL low density lipoprotein
  • the invention may also be of use in confirming or corroborating the results of other diagnostic methods.
  • the diagnosis of the invention may thus suitably be used either as an isolated technique or in combination with other methods and apparatus for diagnosis, in which latter case the invention provides a further test on which a diagnosis may be assessed.
  • Atherosclerosis Complications of atherosclerosis are the most common causes of death in Western societies.
  • atherosclerosis can be considered to be a form of chronic inflammation resulting from interaction modified lipoproteins, monocyte-derived macrophageSjT cells, and the normal cellular elements of the arterial wall. This inflammatory process can ultimately lead to the development of complex lesions, or plaques, that protrude into the arterial lumen. Finally plaque rupture and thrombosis result in the acute clinical complications of myocardial infarction and stroke (Glass et al., Cell 2001, 104:503-516).
  • alleles refers to alternative forms of a gene or portions thereof. Alleles occupy the same locus or position on homologous chromosomes. When a subject has two identical alleles of a gene, the subject is said to be homozygous for the gene or allele. When a subject has two different alleles of a gene, the subject is said to be heterozygous for the gene. Alleles of a specific gene can differ from each other in a single nucleotide, or several nucleotides, and can include substitutions, deletions, and insertions of nucleotides.
  • An allele of a gene can also be a form of a gene containing a mutation.
  • allelic variant of a polymorphic region of a gene refers to a region of a gene having one of several nucleotide sequences found in that region of the gene in other individuals.
  • polymorphism refers to the coexistence of more than one form of a gene or portion thereof.
  • a portion of a gene of which there are at least two different forms, i.e., two different nucleotide sequences, is referred to as a "polymorphic region of a gene".
  • a polymorphic region can be a single nucleotide, the identity of which differs in different alleles.
  • a polymorphic region can also be several nucleotides long.
  • transcription factors are active only if they are phosphorylated on specific residues.
  • transcription factors can be active in the absence of phosphorylated residues and become inactivated by phosphorylation.
  • a list of known transcription factors and their DNA binding site can be found, e.g., in public databases, e.g., TFMATRIX Transcription Factor Binding Site Profile database.
  • Interventions with pharmaceutical agents not yet known whose activity correlates with particular polymo ⁇ hic patterns associated with cardiovascular disease are also encompassed. It is contemplated, for example, that patients who are candidates for a particular therapeutic regimen will be screened for polymo ⁇ hic patterns that correlate with responsivity to that particular regimen.
  • allelic variant of the nucleotide polymo ⁇ hism of nucleotide A or G at position 33 of Seq ID 1 (baySNP179) and that of other possible polymo ⁇ hic regions can be determined in a single hybridization experiment.
  • the whole PCR reaction is transferred into a PSQ plate TM (Pyrosequencing) and prepared using the Sample Prep Tool TM and SNP Reagent Kit TM from Pyrosequencing according to their instructions.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des méthodes diagnostiques et des kits comprenant des oligo et/ou des polynucléotides ou des dérivés associés, notamment des anticorps qui déterminent si un sujet humain présente un risque de subir les effets indésirables d'un médicament après un traitement par statines, si le sujet répond faiblement ou fortement au traitement, ou s'il métabolise bien ou pas les statines. L'invention concerne également des méthodes diagnostiques et des kits comprenant des anticorps qui déterminent si un sujet humain présente un risque pour une maladie cardiovasculaire. L'invention concerne en outre des séquences polymorphiques et d'autres gènes.
PCT/EP2004/000539 2003-01-31 2004-01-23 Polymorphismes de nucleotide simple utilises en tant que diagnostics predictifs d'effet indesirable (adr) et d'efficacite d'un medicament WO2004067774A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04704556A EP1592808A2 (fr) 2003-01-31 2004-01-23 Polymorphismes de nucleotide simple utilises en tant que diagnostics predictifs d'effet indesirable (adr) et d'efficacite d'un medicament

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP03002212.3 2003-01-31
EP03002212 2003-01-31
EP03002153.9 2003-02-03
EP03002153 2003-02-03

Publications (2)

Publication Number Publication Date
WO2004067774A2 true WO2004067774A2 (fr) 2004-08-12
WO2004067774A3 WO2004067774A3 (fr) 2004-10-21

Family

ID=32826771

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/000539 WO2004067774A2 (fr) 2003-01-31 2004-01-23 Polymorphismes de nucleotide simple utilises en tant que diagnostics predictifs d'effet indesirable (adr) et d'efficacite d'un medicament

Country Status (2)

Country Link
EP (1) EP1592808A2 (fr)
WO (1) WO2004067774A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007071382A3 (fr) * 2005-12-22 2007-10-11 Bayer Healthcare Ag Méthode pour prédire des réponses indésirable à un médicament
EP3765516A2 (fr) * 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Molécules multifonctionnelles et utilisations associées
CN115651978A (zh) * 2022-10-13 2023-01-31 解码（上海）生物医药科技有限公司 检测心血管药物疗效和副作用的基因试剂盒及制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1136554A1 (fr) * 2000-03-24 2001-09-26 Bayer Aktiengesellschaft Polymorphismes du gène codant le transporteur à cassette de fixation à l'ATP 1 (ABC1), et usages pour le diagnostique et le traitement de désordres lipidiques, de maladies cardiovasculaires et de maladies inflammatoires

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007071382A3 (fr) * 2005-12-22 2007-10-11 Bayer Healthcare Ag Méthode pour prédire des réponses indésirable à un médicament
EP3765516A2 (fr) * 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Molécules multifonctionnelles et utilisations associées
CN115651978A (zh) * 2022-10-13 2023-01-31 解码（上海）生物医药科技有限公司 检测心血管药物疗效和副作用的基因试剂盒及制备方法

Also Published As

Publication number Publication date
WO2004067774A3 (fr) 2004-10-21
EP1592808A2 (fr) 2005-11-09

Similar Documents

Publication Publication Date Title
JP6211042B2 (ja) 心臓血管障害および薬物応答に関連した遺伝子多型、それらの検出方法および用途
US20100190169A1 (en) Single nucleotide polymorphisms predicting cardiovascular disease
US20090138204A1 (en) Single nucleotide polymorphisms sensitively predicting adverse drug reactions (ADR) and drug efficacy
WO2010006215A1 (fr) Polymorphismes génétiques associés à des maladies cardiovasculaires et procédés de détection et d'utilisation de ceux-ci
US20050123919A1 (en) Single nucleotide polymorphisms predicting adverse drug reactions and medication efficacy
WO2006099365A9 (fr) Polymorphismes genetiques associes a des maladies cardiaques coronariennes, methodes de detection et d'utilisation desdits polymorphismes
US20060240421A1 (en) Genetic polymorphisms sensitively predicting adverse drug reactions (adr) and drug efficacy
WO2004067774A2 (fr) Polymorphismes de nucleotide simple utilises en tant que diagnostics predictifs d'effet indesirable (adr) et d'efficacite d'un medicament
US20090208967A1 (en) Genetic Polymorphisms As Predictive Diagnostics For Adverse Drug Reactions (ADR) And Drug Efficacy
US20090208945A1 (en) Method for the Prediction of Adverse Drug Responses to Stains
US20070265217A1 (en) Single Nucleotide Polymorphisms as Prognostic Tool to Diagnose Adverse Drug Reactions (Adr) and Drug Efficacy
EP1978108A2 (fr) Polymorphismes nucléotides simples pour prédire les maladies cardiovasculaires et efficacité médicale
EP1327639A1 (fr) Prédiction de maladies cardiovasculaires par polymorphisme génétique de genes associés à ces maladies
WO2008052115A1 (fr) Matériaux et procédés permettant de prédire des réponses physiologiques à des médicaments cardiovasculaires

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004704556

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004704556

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)